Strides Pharma Science Ltd

Strides Pharma Science Ltd has announced that its Board of Directors will convene on October 29, 2026. The primary agenda item is the consideration and approval of the unaudited financial results, both standalone and consolidated, for the second quarter and half-year ended September 30, 2026. Additionally, the company has closed the trading window for designated persons from October 1, 2026, which will reopen 48 hours after the financial results are declared, in accordance with the company's insider trading code.

Strides Pharma Science Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter ending September 30, 2026. The specific date for the Board Meeting to approve these results will be communicated separately. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Strides Pharma Science Ltd has released its Sustainability Report for FY26, prepared in accordance with GRI Standards 2021 and SASB standards. The report details the company's non-financial performance across Environmental, Social, and Governance (ESG) parameters, outlining its sustainability framework, strategic plans, challenges, and long-term goals. It also maps initiatives against the United Nations Sustainable Development Goals, underscoring a commitment to responsible business practices and sustainable value creation. The reporting boundary includes all manufacturing facilities, R&D centers, and corporate offices in India, along with subsidiaries in multiple international locations, representing approximately 97% of consolidated revenue.

Strides Pharma Science Ltd announced the completion of a routine USFDA inspection at its formulation facility in Alathur, Chennai. The inspection took place from September 2 to September 11, 2026. The USFDA issued a Form 483 with three observations. The company stated it will respond to these observations within the stipulated time and will inform the stock exchanges of any further updates.

Strides Pharma Science Ltd announced that its flagship manufacturing facility in Bengaluru has received the Establishment Inspection Report (EIR) from the USFDA, signifying the successful closure of the inspection. The inspection, conducted from May 12-20, 2026, initially resulted in a Form 483 with five observations. Strides submitted a comprehensive response and implemented corrective actions, leading the USFDA to classify the outcome as Voluntary Action Indicated (VAI). This clearance reinforces the company's commitment to quality and its regulatory track record, supporting its supply of pharmaceutical products to global markets.

Strides Pharma Science Ltd reported a steady performance for Q1FY27, with revenue growing 13% year-on-year to ₹12,654 million. The Ex-US markets showed robust growth of 17% YoY, contributing ₹5,875 million, while the US business remained steady at ₹6,282 million, up 4% YoY. EBITDA increased by 5.4% YoY to ₹2,298 million, despite a ₹131 million impact from geopolitical disruptions on freight and operating costs. Operational PAT grew 8% YoY to ₹1,231 million. The company also unlocked ₹1,000 million in value through the divestment of its majority stake in Pivot Path, its captive GCC, while retaining meaningful participation. Net debt was reduced by ₹119 million, with Net Debt-to-EBITDA at 1.52x.

Strides Pharma Science Ltd announced the outcome of its Board Meeting held on July 31, 2026. The Board approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. The financial results, along with the Limited Review Report from statutory auditors B S R & Co. LLP, were presented. The meeting commenced at 10:30 hrs IST and concluded at 12:30 hrs IST. The company will make this information available on its website.

Strides Pharma Science Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, on both standalone and consolidated bases. Additionally, the company will address other business matters. In line with the company's insider trading policy, the trading window for designated persons will remain closed from July 1, 2026, until 48 hours after the financial results are declared. The company's website will also host this information.

Strides Pharma Science Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's corporate identity, operational structure, and market presence. It covers standalone financial disclosures and consolidated other disclosures for Strides and its wholly-owned Indian subsidiary, Arcolab. The company operates in the manufacturing of pharmaceuticals, with 100% turnover from this segment. Strides serves a global market, with exports contributing 90.66% to its standalone turnover. The report also outlines employee and worker statistics as of FY26, with a total of 2,810 employees and 2,584 workers.

Strides Pharma Science Ltd has announced that its 35th Annual General Meeting (AGM) will be held on Friday, August 14, 2026, at 12:15 hrs IST. The meeting will be conducted through Video Conference/Other Audio-Visual Means (VC/OAVM). The company will also be presenting its Annual Report for FY2025-26, including the Business Responsibility and Sustainability Report. Key dates for shareholders include a cut-off date of August 7, 2026, for e-voting eligibility, with the e-voting period running from August 10 to August 13, 2026. The record date for dividend is July 31, 2026. The AGM will cover ordinary business, including the adoption of the Audited Financial Statements for FY2025-26.